---
title: "Lysergide (DT120) in Generalized anxiety disorder: Phase of product development"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Phase of product development. Topics: Regulatory status: Submission planned; NDA filing anticipated in the first half of 2027, Commercial readiness and launch preparation: no launch date stated, Investigational status and current development phase, Phase 3 topline results: Voyage reported August 2026 and Panorama reported September 2026, and 18 further topics. 22 evidence topics quoted from 23 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/phase-of-product-development"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Phase of product development

<a id="heading-2.1.1"></a>

## 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

### Regulatory status: Submission planned; NDA filing anticipated in the first half of 2027

> “On track for DT120 ODT NDA filing in first half of 2027”

Source: [Definium Therapeutics third quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/259/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights)

> “Pre-NDA meeting scheduled in 4Q 2026; NDA filing anticipated in 1H 2027”
> “Building on this momentum, we are advancing toward an NDA submission and look forward to aligning with the FDA at our upcoming pre-NDA meeting.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “the timing of our pre-NDA meeting scheduled for the fourth quarter of 2026; our anticipated NDA filing in the first half of 2027”
> “Regulatory filing strategy for GAD & MDD to be discussed at pre-NDA meeting.”
> “Robust data package aligned with FDA guidance supports advancement of NDA submission for DT120 ODT”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-2.1.1-2"></a>

### Launch

No evidence found.

<a id="topic-2.1.1-3"></a>

### Commercial readiness and launch preparation: no launch date stated

> “Advancing commercial readiness activities and expanding organizational capabilities to support the Company’s transition toward commercialization.”
> “The Company is also planning its first Commercial Day in the first half of 2027 to highlight the market opportunity for DT120 ODT and provide greater detail on its commercialization strategy and launch preparations.”

Source: [Definium Therapeutics third quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/259/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights)

> “Timing estimates subject to clinical progress and regulatory interactions.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-2.1.1-4"></a>

### Investigational status and current development phase

> “Our lead product candidate, DT120 (Lysergide) orally disintegrating tablet (“ODT”), is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that we are developing for the treatment of adults with generalized anxiety disorder (“GAD”), major depressive disorder (“MDD”) and posttraumatic stress disorder (“PTSD”).”
> “Our Phase 3 clinical program for DT120 ODT for GAD consists of two clinical trials: the Voyage study (DT120-300) and the Panorama study (DT120-301).”
> “Both trials are comprised of two parts: Part A, which is a 12-week, randomized, double-blind, placebo-controlled, parallel-group trial assessing the efficacy and safety of DT120 ODT versus placebo; and Part B, which is a 40-week extension period during which participants will be eligible for open-label treatment with DT120 ODT, subject to certain conditions for treatment eligibility.”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

> “The Company's products will not be commercialized prior to applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the intended uses is successfully developed.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-2.1.1-5"></a>

### Phase 3 topline results: Voyage reported August 2026 and Panorama reported September 2026

> “On August 12, 2026, we announced that the Voyage study met its primary endpoint and all key secondary efficacy endpoints, demonstrating a statistically significant and clinically meaningful improvement from baseline compared with placebo, as measured by the change in HAM-A total score at Week 12.”
> “On September 14, 2026, we announced that the Panorama study met its primary endpoint and all key secondary efficacy endpoints”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

> “Reported positive topline Phase 3 results from two Phase 3 studies of DT120 ODT in generalized anxiety disorder (GAD)”

Source: [Definium Therapeutics third quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/259/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights)

<a id="topic-2.1.1-6"></a>

### Phase 3 initiation: first participant dosed in Voyage in December 2024

> “today announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD) for the treatment of GAD.”

Source: [MindMed Voyage first patient dosed announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/169/mindmed-announces-first-patient-dosed-in-phase-3-voyage-study-of-mm120-in-generalized-anxiety-disorder-gad)

<a id="topic-2.1.1-7"></a>

### Breakthrough Therapy designation for generalized anxiety disorder: March 2024

> “today announced that FDA has granted breakthrough designation to its MM120 (lysergide d-tartrate) program for the treatment of generalized anxiety disorder (GAD).”
> “Based on the significant unmet medical need in the treatment of GAD – especially in patients who do not respond to or tolerate currently available medications – along with the initial clinical data from Phase 2b and other research conducted by MindMed, the U.S. Food & Drug Administration (FDA) has designated MM120 for GAD as a breakthrough therapy.”

Source: [MindMed Breakthrough Therapy designation announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/137/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder)

> “In March 2024, we announced that the U.S. Food and Drug Administration (“FDA”) granted breakthrough designation to our DT120 program for the treatment of GAD.”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

<a id="topic-2.1.1-8"></a>

### Breakthrough Therapy designation for major depressive disorder: September 2026

> “today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for DT120 (lysergide) ODT.”
> “This milestone marks the second Breakthrough Therapy designation from the FDA for the DT120 development program, following its initial designation for the potential treatment of GAD.”

Source: [Definium Therapeutics MDD Breakthrough Therapy designation announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/247/definium-therapeutics-receives-breakthrough-therapy-designation-for-dt120-lysergide-orally-disintegrating-tablet-odt-in-major-depressive-disorder-mdd-following-positive-phase-3-results)

<a id="topic-2.1.1-9"></a>

### End-of-phase 2 meeting with the FDA: completed June 2024

> “today announced the completion of the End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of MM120 (lysergic acid diethylamide [LSD] D-tartrate) into pivotal trials for the treatment of adults with GAD.”
> “Following a constructive End-of-Phase 2 meeting with the FDA, we are pleased to have reached alignment on our Phase 3 development strategy for MM120 in GAD,”
> “The EOP2 meeting was supported by results from MindMed’s completed Phase 2b clinical trial, MMED008.”

Source: [MindMed end-of-phase 2 meeting announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/149/mindmed-announces-constructive-end-of-phase-2-meeting-with-u-s-fda-for-mm120-in-generalized-anxiety-disorder-gad)

<a id="topic-2.1.1-10"></a>

### Investigational new drug application for the phase 2b trial: cleared January 2022

> “announced today that the U.S. Food and Drug Administration (FDA) has cleared MindMed's Investigational New Drug (IND) application, allowing the Company's Phase 2b dose-optimization trial of MM-120 for the treatment of generalized anxiety disorder (GAD) to proceed.”
> “The previously announced clinical hold on the IND was lifted following MindMed's rapid responses for additional information related to the participant monitoring protocol in the upcoming study.”

Source: [MindMed IND clearance announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/54/fda-clears-mindmed-ind-for-mm-120-in-treatment-of-generalized-anxiety-disorder)

<a id="topic-2.1.1-11"></a>

### Innovation Passport under the UK Innovative Licensing and Access Pathway: December 2024

> “today announced that MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD), has been granted an Innovation Passport for the potential treatment of GAD under ILAP by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).”
> “Specific benefits of ILAP include the potential for a 150-day accelerated Marketing Authorization Application assessment, rolling review and a continuous benefit risk assessment.”

Source: [MindMed Innovation Passport announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/167/mindmed-awarded-innovation-passport-designation-by-the-united-kingdom-uk-innovative-licensing-and-access-pathway-ilap-steering-group-for-mm120-orally-disintegrating-tablet-odt-for-generalized-anxiety-disorder-gad)

<a id="topic-2.1.1-12"></a>

### Development outside the United States: regulatory strategy

> “evaluate the market potential and regulatory pathways for our product candidates in the UK, European Union (the “EU”), and other countries or regions outside the United States, and determine the best strategic and business opportunities to advance our product candidates in these markets;”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-2.1.1-13"></a>

### Controlled substance scheduling: rescheduling by the DEA and states required after approval

> “Certain product candidates we are developing contain Schedule I controlled substances, like lysergide or MDMA, as defined in the Controlled Substances Act (“CSA”). Our product candidates must be approved by the FDA through the NDA process, and will need to be rescheduled by the Drug Enforcement Administration (“DEA”) and states, before they may be legally marketed in the U.S.”
> “If DT120 and DT402 receive FDA approval, HHS and the DEA must complete a scheduling analysis and make a scheduling determination to deschedule or place either the substance or the drug product in a schedule other than Schedule I in order for them to be able to be prescribed to patients in the United States.”
> “The rescheduling process requires the DEA to conduct notice-and-comment rulemaking, including issuing an interim final rule 90 days after the later of notice of FDA approval or DEA receipt of the HHS scheduling analysis and recommendation.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

> “legislative and regulatory developments, including decisions by the Drug Enforcement Administration and states to reschedule any of the Company's product candidates, if approved, containing Schedule I controlled substances, before they may be legally marketed in the U.S.”

Source: [Definium Therapeutics third quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/259/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights)

<a id="topic-2.1.1-14"></a>

### Executive Order 14401 of April 2026: priority vouchers and timely rescheduling of psychedelic drugs

> “The Commissioner of Food and Drugs shall provide Commissioner's National Priority Vouchers to appropriate psychedelic drugs that have received a Breakthrough Therapy designation and are in accordance with the criteria of the National Priority Voucher Program.”
> “Timely Rescheduling. The Attorney General shall, in consultation with HHS, initiate and complete review of any product containing a Schedule I substance that has successfully completed Phase 3 clinical trials for a serious mental health disorder, so that rescheduling, if appropriate under 21 U.S.C. 811, may proceed as quickly as practicable for such specific products that are ultimately approved under section 505 of the Federal Food, Drug, and Cosmetic Act.”

Source: [Executive Office of the President (2026)](https://www.federalregister.gov/documents/2026/04/22/2026-07907/accelerating-medical-treatments-for-serious-mental-illness)

> “The Executive Order directs coordinated federal action to prioritize mental health therapies, streamline regulatory pathways, and expand cross-agency collaboration, consistent with the Administration’s policy to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic medicines that could help save lives and address the serious mental health crisis in America.”

Source: [Definium Therapeutics executive order statement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/221/definium-therapeutics-applauds-white-house-executive-order-to-accelerate-mental-health-innovation-and-expand-access-to-psychedelic-medical-treatments)

<a id="topic-2.1.1-15"></a>

### Patent protection for the orally disintegrating tablet

> “The newly issued patent (USPN 12,036,220) includes claims covering the pharmaceutical formulation, methods of manufacturing and method of treatment for MM120 ODT, MindMed’s proprietary and pharmaceutically optimized form of lysergide (LSD).”
> “The pharmaceutical formulation patent is the first US patent issued on the MM120 ODT formulation and extends the Company’s intellectual property protection for MM120 through 2041.”

Source: [MindMed ODT patent announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/152/mindmed-announces-issuance-of-new-patent-for-mm120-orally-disintegrating-tablet-odt)

> “For lysergide, these patents and patent applications are directed to methods of treatment, analytical methods, compositions of matter, and formulations.”
> “If issued, the 20-year term expiration dates from which our patents will expire is between 2041 to 2044, not including any extension of the patent term that may be available in certain jurisdictions.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-2.1.1-16"></a>

### NDA submission timing: no date stated, April 2026, superseded in September 2026

> “Together, these trial outcomes will inform our regulatory approach, including an expeditious path to a potential NDA submission.”

Source: [Definium Therapeutics Investor and Analyst Day announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/223/definium-therapeutics-highlights-dt120-odt-lysergide-tartrate-clinical-advancements-and-commercial-strategy-at-investor-and-analyst-day)

<a id="topic-2.1.1-17"></a>

### Voyage topline timing: first half of 2026, stated March 2025 to November 2025, superseded in January 2026

> “the Company’s anticipated topline readout (Part A results) for the Phase 3 Voyage study of MM120 ODT in GAD in the first half of 2026”

Source: [MindMed full-year 2024 results announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/175/mindmed-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-business-updates)

> “Topline data for Voyage is expected in the first half of 2026 and for Panorama and Emerge in the second half of 2026.”

Source: [MindMed JAMA publication announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/192/journal-of-the-american-medical-association-jama-publishes-results-from-first-ever-randomized-placebo-controlled-clinical-trial-assessing-the-dose-dependent-efficacy-of-mm120-lysergide-d-tartrate-lsd-in-generalized-anxiety-disorder-gad)

> “the Company’s anticipated topline readout (Part A results) for the Phase 3 Voyage study of MM120 ODT in GAD in the first half of 2026”

Source: [MindMed third quarter 2025 results announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/203/mindmed-reports-q3-2025-financial-results-and-business-updates)

<a id="topic-2.1.1-18"></a>

### Voyage topline timing: second quarter of 2026, stated January 2026, superseded in February 2026

> “Topline Data from Three Phase 3 Studies Evaluating DT120 Orally Disintegrating Tablet (ODT) for GAD and MDD Expected in 2026: Voyage in 2Q, Panorama in 2H, and Emerge Mid-Year”

Source: [Definium Therapeutics rebrand announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/207/mindmed-rebrands-to-definium-therapeutics-advancing-a-leading-late-stage-psychiatry-pipeline-with-three-phase-3-readouts-expected-in-2026)

<a id="topic-2.1.1-19"></a>

### Voyage topline timing: early third quarter of 2026, stated February 2026 to May 2026, superseded in August 2026

> “the Company’s anticipated topline readout (Part A results) for the Phase 3 Voyage study of DT120 ODT in GAD in early 3Q 2026”

Source: [Definium Therapeutics full-year 2025 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/215/definium-therapeutics-reports-full-year-2025-financial-results-and-business-updates)

> “GAD: Voyage enrollment complete with 214 patients with topline data readout on track for early 3Q 2026”

Source: [Definium Therapeutics Investor and Analyst Day announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/223/definium-therapeutics-highlights-dt120-odt-lysergide-tartrate-clinical-advancements-and-commercial-strategy-at-investor-and-analyst-day)

> “the Company’s anticipated topline readout (Part A results) for the Phase 3 Voyage study of DT120 ODT in GAD in early 3Q 2026”

Source: [Definium Therapeutics first quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/225/definium-therapeutics-reports-first-quarter-2026-financial-results-and-recent-highlights)

<a id="topic-2.1.1-20"></a>

### Panorama topline timing: second half of 2026, stated March 2025 to February 2026, superseded in April 2026

> “the Company’s anticipated topline readout (Part A results) for the Phase 3 Panorama study for MM120 ODT in GAD in the second half of 2026”

Source: [MindMed full-year 2024 results announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/175/mindmed-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-business-updates)

> “the Company’s anticipated topline readout (Part A results) for the Phase 3 Panorama study for MM120 ODT in GAD in the second half of 2026”

Source: [MindMed third quarter 2025 results announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/203/mindmed-reports-q3-2025-financial-results-and-business-updates)

> “Panorama: study enrollment on track with topline data anticipated in 2H 2026.”

Source: [Definium Therapeutics full-year 2025 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/215/definium-therapeutics-reports-full-year-2025-financial-results-and-business-updates)

<a id="topic-2.1.1-21"></a>

### Panorama topline timing: late third quarter of 2026, stated April 2026 and May 2026, superseded in August 2026

> “Topline data now anticipated in late 3Q 2026 (updated from 2H 2026).”

Source: [Definium Therapeutics Investor and Analyst Day announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/223/definium-therapeutics-highlights-dt120-odt-lysergide-tartrate-clinical-advancements-and-commercial-strategy-at-investor-and-analyst-day)

> “Topline data expected in late 3Q 2026 (updated from 2H 2026).”

Source: [Definium Therapeutics first quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/225/definium-therapeutics-reports-first-quarter-2026-financial-results-and-recent-highlights)

> “the Company’s anticipated topline readout (Part A results) for the Phase 3 Panorama study for DT120 ODT in GAD in September 2026”

Source: [Definium Therapeutics second quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/242/definium-therapeutics-reports-second-quarter-2026-financial-results-and-recent-highlights)

<a id="topic-2.1.1-22"></a>

### Phase 3 initiation planned for the second half of 2024, stated March 2024 and June 2024, superseded in December 2024

> “The Company plans to hold an End-of-Phase 2 meeting with the FDA in the first half of 2024 and initiate a Phase 3 clinical program in the second half of 2024.”

Source: [MindMed Breakthrough Therapy designation announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/137/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder)

> “We are on schedule to initiate our Phase 3 clinical program for MM120 oral dissolving tablet (ODT) in GAD in the second half of this year and look forward to sharing additional details on the design of our pivotal program in the coming months.”

Source: [MindMed end-of-phase 2 meeting announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/149/mindmed-announces-constructive-end-of-phase-2-meeting-with-u-s-fda-for-mm120-in-generalized-anxiety-disorder-gad)

<a id="topic-2.1.1-23"></a>

### FDA clinical hold on the phase 2b IND, December 2021, superseded in January 2022

> “today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its IND submission intended to support the initiation of a Phase 2b trial of lysergic acid diethylamide (LSD) for the treatment of generalized anxiety disorder (GAD).”
> “Additional detail regarding the FDA's decision is expected within 30 days.”

Source: [MindMed IND clinical hold announcement (2021)](https://ir.definiumtx.com/news-events/press-releases/detail/60/mindmed-provides-status-update-on-ind-for-phase-2b-trial-of-lsd-for-the-treatment-of-generalized-anxiety-disorder)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
